Kestra Medical Technologies stock overview

Kestra Medical Technologies (KMTS) has drawn attention after recent trading left the shares at a last close of US$20.05, with returns under pressure over the month and past 3 months.

For readers tracking performance, the stock shows a 0.6% gain over the past day, a 2.6% decline over the past week, an 11.9% decline over the month, and a 24.4% decline over the past 3 months.

See our latest analysis for Kestra Medical Technologies.

That near term weakness fits into a tougher stretch for holders, with a year to date share price return of a 17.8% decline and a 1 year total shareholder return of a 22% loss, suggesting momentum has faded recently.

If you are weighing what else to watch in healthcare technology, it could be worth scanning for other cardiology and monitoring names through our curated list of 33 healthcare AI stocks

With Kestra Medical Technologies combining double digit revenue growth, ongoing losses of US$148.121 million and a market value of about US$1.16b, investors now face the key question: is there discounted upside here or is the market already pricing in future growth?

Most Popular Narrative: 31.2% Undervalued

With the most followed fair value estimate at $29.14 against a last close of $20.05, the current price sits well below that narrative anchor.

Category underpenetration in the U.S. with only 14% of eligible patients currently using a wearable defibrillator creates a long runway for adoption, supporting sustained double digit prescription growth and accelerating revenue expansion.

Read the complete narrative.

Curious how a single underused therapy, ambitious margin goals and rising payer coverage might combine into that valuation story? The full narrative spells out the revenue, earnings and reuse assumptions that sit behind this fair value line line by line.

Result: Fair Value of $29.14 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this story can change quickly if wearable defibrillator adoption stalls at current U.S. penetration, or if ongoing losses and spending continue to outpace Kestra’s revenue base.

Find out about the key risks to this Kestra Medical Technologies narrative.

Another way to look at valuation

The analyst narrative leans on future earnings and a fair value of $29.14, but the current P/S of 14x tells a very different story. It is well above the US Medical Equipment industry at 2.7x, the peer average at 8.4x, and even the fair ratio estimate of 3.8x. This points to considerable valuation risk if expectations reset.

For a closer look at what this gap might mean in practice, including the detailed ratio work that underpins that fair ratio, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment mixed through this review, it makes sense to move quickly, review the underlying data yourself and weigh up the 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Kestra has you thinking more broadly about your portfolio, do not stop here, the next opportunity you shortlist could come from a fresh screener result.

• Spot potential underpriced leaders early by scanning our list of 63 high quality undervalued stocks that pair quality fundamentals with attractive valuations.
• Strengthen your income stream by reviewing 12 dividend fortresses built to highlight companies combining higher yields with resilient payout histories.
• Protect your downside by focusing on 65 resilient stocks with low risk scores that score well on stability and financial resilience before risks show up in the headlines.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.